ClinicalTrials.gg
Not yet recruitingNCT07768696Updated Aug 17, 2026

Oral Immunotherapy for Children With Cow's Milk Allergy

An interventional study of Oral immunotherapy with cow's milk in Milk Allergy, Cow's, Food Allergy in Children and Food Allergies, sponsored by Laura Ozer Kettner. Not yet recruiting at 5 sites in Denmark. Open to participants aged 6 Months to 18 Months. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Laura Ozer Kettner · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
6 Months to 18 Months
Sex
All
01

Study summary

This clinical trial aims to investigate if oral immunotherapy can help children with cow's milk allergy tolerate cow's milk.

Children aged 6-18 months can take part in the trial.

Main question: What percentage of children can tolerate cow's milk after oral immunotherapy, compared with children who avoid cow's milk?

Children are assigned to these two groups by chance.

Children receiving oral immunotherapy will:

  • Take a small, increasing amount of cow's milk daily for 1-1.5 years
  • Attend clinic or online visits each time the dose is increased
  • Record missed doses

All children will:

  • Provide blood samples to measure allergy-related markers
  • Undergo an oral food challenge with cow's milk after 1-1.5 years to assess how much they can tolerate
  • Report allergic reactions (parent-reported)
  • Complete questionnaires (parent-reported)
  • Participate in an end-of-study telephone interview with an allergy nurse (parent-reported)
02

Conditions studied

  • Milk Allergy, Cow's
  • Food Allergy in Children
  • Food Allergies

Keywords

  • Oral immunotherapy
  • OIT
  • Desensitization
03

In context

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's planned enrollment of 56 is below the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Laura Ozer Kettner is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 to 18 months
  • Cow's milk allergy confirmed at an oral food challenge
  • Reaction threshold below 300 mg of cow's milk protein at the oral food challenge
  • Specific IgE to cow's milk > 0.35 kU/L
  • High risk of persistent allergy to cow's milk (based on defined criteria)
  • Family motivated for oral immunotherapy following shared decision-making using a decision aid

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled asthma, eczema, rhino-conjunctivitis, urticaria, or eosinophilic esophagitis
  • Treatment with biologic or medication
  • Non-Danish-speaking families
  • Anticipated non-adherent families
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Oral immunotherapy

    Children randomized to oral immunotherapy will ingest a daily dose of cow's milk. Dose escalation will be performed approximately every two weeks at the allergy clinic or via online consultations. After approximately 6 months, a maintenance dose of 300 mg food protein will be reached and continued daily for 6-12 months.

    Other: Oral immunotherapy with cow's milk

  • No intervention
    Avoidance

    Children randomized to avoidance will receive standard care for cow's milk allergy, including avoidance of cow's milk.

Interventions

  • OtherOral immunotherapy with cow's milk

    Oral immunotherapy with cow's milk for 1-1.5 years

06

What researchers measure

Primary outcomes

  1. Tolerance to cow's milk (4000 mg)

    Proportion of children who tolerate a cumulative dose of 4343 mg of cow's milk protein at an oral food challenge

    Time frame: 1-1.5 years after enrollment

Secondary outcomes

  1. Early tolerance to cow's milk (4000 mg)

    Proportion of children, with a 50% or greater reduction in cow's milk-specific IgE after 1 year, who tolerate a cumulative dose of 4343 mg of cow's milk protein at an oral food challenge

    Time frame: 1 year after enrollment

  2. Tolerance to cow's milk (1000 mg)

    Proportion of children who tolerate a cumulative dose of 1343 mg of cow's milk protein at an oral food challenge

    Time frame: 1-1.5 years after enrollment

  3. Allergic reactions

    Proportion of children experiencing allergic reactions, graded by the World Allergy Organization grading system

    Time frame: 1-1.5 years and 2-2.5 years (end of study) after enrollment

  4. Use of adrenaline auto-injector

    Proportion of children who used an adrenaline auto-injector due to allergic reactions

    Time frame: 1-1.5 years and 2-2.5 years (end of study) after enrollment

  5. Parental food allergy related quality of life

    Changes in quality of life scores measured by the Food Allergy Quality of Life - Parental Burden Questionnaire

    Time frame: At enrollment, 1-1.5 years, and 2-2.5 years (end of study) after enrollment

  6. Parental food allergy related anxiety

    Changes in anxiety scores measured by the Impairment Measure for Parental Food Allergy-Associated Anxiety and Coping Tool (IMPAACT)

    Time frame: At enrollment, 1-1.5 years, and 2-2.5 years (end of study) after enrollment

  7. Biomarkers

    Changes in specific IgEs and Basophil Activation Test

    Time frame: At enrollment, 1-1.5 years, and 2-2.5 years (end of study) after enrollment

  8. Study dropout

    Proportion of children who dropped out

    Time frame: 1-1.5 years and 2-2.5 years (end of study) after enrollment

  9. Regular cow's milk intake

    Proportion of children with regular intake of cow's milk after allergy resolves

    Time frame: 2-2.5 years (end of study) after enrollment

  10. Missed oral immunotherapy doses

    Proportion of missed oral immunotherapy-doses

    Time frame: During up-dosing and maintenance phase

  11. Is oral immunotherapy worth it

    Proportion of families who considered oral immunotherapy worthwhile, and their reported key benefits and burdens

    Time frame: After oral immunotherapy and at 2-2.5 years (end of study) after enrollment

  12. Decision aid

    Scores on the Decisional Conflict Scale

    Time frame: Right after decision to start oral immunotherapy

07

Study locations

5 sites
08

References and documents

Publications

  • Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Carr S, Custovic A, Durham S, Ebisawa M, Geller M, Gonzalez-Estrada A, Greenberger PA, Hossny E, Irani C, Leung ASY, Levin ME, Muraro A, Oppenheimer JJ, Ortega Martell JA, Pouessel G, Rial MJ, Senna G, Tanno LK, Wallace DV, Worm M, Morais-Almeida M; WAO Anaphylaxis Committee and WAO Allergen Immunotherapy Committee. Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee. World Allergy Organ J. 2024 Feb 10;17(3):100876. doi: 10.1016/j.waojou.2024.100876. eCollection 2024 Mar. PubMed 38361745 ↗
  • O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. doi: 10.1177/0272989X9501500105. PubMed 7898294 ↗
  • To S, Westwell-Roper C, Soller L, Stewart SE, Chan ES. Development of IMPAACT (Impairment Measure for Parental Food Allergy-Associated Anxiety and Coping Tool), a validated tool to screen for food allergy-associated parental anxiety. Ann Allergy Asthma Immunol. 2022 Oct;129(4):451-460.e3. doi: 10.1016/j.anai.2022.02.020. Epub 2022 Mar 4. PubMed 35248728 ↗
  • Cohen BL, Noone S, Munoz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. J Allergy Clin Immunol. 2004 Nov;114(5):1159-63. doi: 10.1016/j.jaci.2004.08.007. PubMed 15536425 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to ethical and data protection considerations

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07768696
Lead sponsor
Laura Ozer Kettner
Collaborators
Randers Regional Hospital, Gødstrup Hospital, Viborg Regional Hospital, Kolding Sygehus
Responsible party
Laura Ozer Kettner (Doctor, Aarhus University Hospital) — Sponsor-investigator
First posted
Aug 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Sep 2031 (estimated)
Last update
Aug 17, 2026

Study contacts

Laura O Kettner, MD, PhD
Contact
lauchr@rm.dk
+45 51703229
Sune LM Rubak, MD, PhD
Contact
sunerubak@skejby.rm.dk
+45 51729258
Laura O Kettner, MD, PhD
principal investigator · The Danish Center of Pediatric Pulmonology and Allergology, Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion